Global News

Angle, MD Anderson Cancer Center collaborate on colorectal cancer

Wednesday, February 18, 2015 11:49 AM

Angle, a specialist medtech company based in England, is collaborating with the MD Anderson Cancer Center to investigate the clinical use of Angle's Parsortix system as a companion diagnostic in colorectal cancer. The University of Texas MD Anderson Cancer Center is a center devoted exclusively to cancer patient care, research, education and prevention.

More... »


The Keys to success in Site Selection

Tuesday, February 17, 2015 08:00 AM

The keys to successful study conduct at the site level are honesty, integrity and transparency:

More... »


Janssen R&D launches three new research platforms

Friday, February 13, 2015 11:35 AM

Janssen R&D, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has launched three new research platforms focused on disease prevention, disease interception and the microbiome—areas of transformational medical innovation that are expected to change the healthcare landscape. The new teams will collaborate closely with Janssen’s five therapeutic areas as well as external partners, to underpin ongoing research and propel scientific knowledge.

More... »

Affinivax, PATH collaborate on pneumococcal disease vaccine candidate

Friday, February 13, 2015 11:30 AM

Affinivax, a Cambridge, Mass.-based biotechnology company dedicated to developing novel vaccines, has entered into a collaboration with PATH, a global health nonprofit organization, to advance the company’s lead vaccine candidate for Streptococcus pneumoniae (pneumococcus). The partnership includes funding from PATH to support product development, preclinical testing and manufacturing, with the goal to qualify and select a final development candidate to advance toward clinical testing.

More... »

PharmaTimes clinical research awards to be presented Feb. 26

Thursday, February 12, 2015 03:33 PM

The 2015’s PharmaTimes Clinical Researcher of the Year—The Americas awards will be presented Feb. 26 in North Carolina.

More... »

Molecular Response sells business unit to Crown Bioscience

Thursday, February 12, 2015 03:00 PM

Molecular Response (MRL), a privately held molecular diagnostic services company based in San Diego, Calif., has sold its PDX business unit to Crown Bioscience, a drug discovery and development service company headquartered in Santa Clara, Calif.

More... »

Inventiv Health to open new clinic in Miami

Thursday, February 12, 2015 01:13 PM

inVentiv Health, a Princeton, N.J.-based provider of clinical development and commercialization services, will open a new phase I/IIA clinic in Miami, expanding its phase I clinical services to the U.S.

More... »

Thiel Foundation's Breakout Labs selects three early-stage companies for funding

Thursday, February 12, 2015 01:05 PM

Breakout Labs, a seed-stage revolving fund operating out of the nonprofit Thiel Foundation in San Francisco, has announced three new companies have been selected for funding. These companies include Neumitra, Ion Dx, E3XBio.

More... »

Advaxis, Incyte collaborate on early stage cervical cancer immunotherapies

Thursday, February 12, 2015 01:04 PM

Advaxis, a Princeton, N.J.-based clinical-stage biotechnology company developing cancer immunotherapies, has entered into a clinical trial collaboration agreement with Incyte to evaluate the combination of Advaxis's Lm-LLO cancer immunotherapy, ADXS-HPV (ADXS11-001), with Incyte's investigational oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, epacadostat (INCB24360). Incyte is a pharmaceutical company based in Alapocas, Del.

More... »

Voyager Therapeutics, Genzyme collaborate on CNS disorders

Thursday, February 12, 2015 01:01 PM

Voyager Therapeutics, a gene therapy company headquartered in Cambridge, Mass. developing treatments for diseases of the central nervous system (CNS), and Genzyme, a Sanofi company and gene therapy pioneer, have announced a major strategic collaboration to discover, develop and commercialize novel gene therapies for severe CNS disorders. The collaboration will leverage Genzyme’s long-standing commitment and experience in adeno-associated virus (AAV) gene therapy and Voyager’s AAV product engine to develop breakthrough therapies for patients suffering from severe CNS disorders.

More... »

`

CWWeekly

February 23

Venture capital investors funding novel drug R&D three times more than companies repurposing, improving existing drugs

In appreciation: Karen Woodin will be remembered for her teaching, writing and lasting friendships

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

February

Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

January

All eyes on EMA’s adaptive licensing pilot
Sponsors could offer innovative drugs to patients 8 years sooner

Ice Bucket Challenge a boon for ALS research
Donations soar, but phenomenon difficult to replicate

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs